Premium
The role of cystatin‐C and fetuin‐A in the determination of early atherosclerotic risk in psoriasis patients
Author(s) -
Demirbaş Abdullah,
Kurtipek Gülcan Saylam,
Tunçez Abdullah,
Akyürek Fikret,
Demirbaş Gözde Ulutaş
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13898
Subject(s) - medicine , cystatin c , psoriasis , creatinine , triglyceride , renal function , intima media thickness , gastroenterology , cholesterol , c reactive protein , endocrinology , risk factor , inflammation , immunology , carotid arteries
Psoriasis is associated with an increased risk of atherosclerosis. The objective of this study is evaluate the relationship between carotid intima‐media thickness (CIMT) serum and cystatin‐C, fetuin‐A levels in determining the increased risk of subclinical atherosclerosis in psoriasis patients. In this study, age and gender compatible 80 psoriasis patients and 78 healthy individuals were included. For both groups, serum cystatin‐C, fetuin‐A, high‐sensitivity C‐reactive protein (hs‐CRP), oxidized low‐density lipoprotein (ox‐LDL), low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), triglyceride, total cholesterol, and creatinine levels were recorded and carotid intima‐media thickness (CIMT) was measured via B‐mode ultrasonography by cardiology department. In binary comparisons between patient and control groups, cystatin‐C, fetuin‐A, hs‐CRP, and CIMT values were higher in psoriasis patients and there was a statistically significant difference ( P < .05). In control group, serum HDL‐C level was statistically significant higher ( P < .05). There was no statistically significant difference in hs‐CRP, ox‐LDL, LDL‐C, triglyceride, total cholesterol, and creatinine levels between the groups ( P > .05). Our study supported that psoriasis is a risk factor for development of atherosclerosis and we think that cystatin‐C can be used as an important marker in determining subclinical atherosclerosis in patients with psoriasis.